We follow the genome
Visionary team of seasoned executives have built an integrated platform to achieve durable, high-quality weight management. Every mechanism we pursue is anchored in validated biology.
Sustainable weight loss
Solving for what happens after weight loss
We are building next-generation treatments designed to sustain results, helping patients maintain progress over time through better biology and a more practical approach to real-world use.
Alveus Therapeutics is focused on what comes next in metabolic medicine
Current therapies have shown that weight loss is achievable. The question we're focused on is what comes next: now that you've lost the weight, how do you stay healthy and stable for years to come? Is the biology of the maintenance phase fundamentally different from the biology of weight loss itself? And if so, doesn't it deserve a fundamentally different approach?
~1.5B
adults living with obesity by 2035
5-10%
of eligible patients currently treated
4x a year
The number of injections ALV-100 could require for maintenance
75+ years
combined leadership experience within the metabolic area
Our science The science exists.
The science exists.
We address the gaps.
Meeting the future needs
Creating a comprehensive, stage-spanning patient support by focusing on quality of weight loss, improved tolerability, and patient-friendly dosing regimens. With positive patient experience and superior adherence, we are on a strong path to win future market dynamics.
Differentiated pipeline
Our ongoing and planned studies testing ALV-100, a GIPR mAb/GLP-1RA fusion protein, dosed every three or six months in maintenance, could represent a significant improvement compared to currently available options. Our highly differentiated preclinical Amylin portfolio will offer distinguished all-rounder patient support.
Our treatments are designed to address both weight loss and long-term weight maintenance.
Development pipeline
A differentiated therapeutic portfolio built for every patient journey
Alveus's pipeline is focused on next-generation metabolic therapies; the lead asset ALV-100 is currently in Phase 2. The company's preclinical amylin pipeline consists of novel peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.
ALV-100
GIPR antagonism + GLP-1R agonism
ALV-200
Amylin pathway, metabolic set-point
Amylin Small Molecule
Oral amylin mimetic, broad access
Fourth program
Novel metabolic mechanism
Alveus Leadership
The team that knows what it takes
Our experienced leadership team brings proven success in metabolic disease drug development and pipeline building, backed by a Board with expertise across key functional areas.
Raj Kannan Chief Executive Officer
Jacob Jeppesen, PhD CSO and Head of R&D
Marie Lindegaard Chief Financial Officer
Thomas Hansen Chief Operating Officer
Every program starts with a molecule - and is carried forward by a team, a strategy, and an unrelenting commitment to patients.
What separates Alveus from the rest
We follow the genome
Every mechanism we pursue has human loss-of-function validation. GIPR variants that silence the receptor protect against obesity, heart disease, and metabolic complications, independent of GLP-1. The science told us where to look. We listened.
A shot every three months
ALV-100 is designed for quarterly maintenance dosing, the longest interval of any asset in clinical development. That is not an incremental improvement. That is a fundamentally different life for patients.
Built to keep the weight off
GIPR antagonism suppresses the counterregulatory responses that drive weight regain after therapy ends. In our Phase 1 data, patients held their weight below baseline through 150 days of follow-up, long after GLP-1 levels had declined.
Three mechanisms. One company
ALV-100 plus two proprietary amylin programs, a selective injectable peptide and an oral small molecule, give partners three distinct mechanisms and multiple shots on goal in the largest therapeutic market of the decade.
News & Events
Latest from Alveus Therapeutics
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
ALV-100 Phase 2 Trial Doses First Patient in Long-Term Weight Maintenance Study
Alveus Presents Preclinical Amylin Portfolio Data at Metabolic Disease Congress
Clinical trial
ALV-100 is now enrolling for the Phase 2 long-term maintenance study. Learn more about participation and eligibility.
Investors & Partners
Backed by the best in biotech
Series A Investors
